Applied Therapeutics, Inc. (APLT)
| Previous Close | 1.1200 |
| Open | 0.9400 |
| Bid | 0.9500 x 1000 |
| Ask | 0.9650 x 1000 |
| Day's Range | 0.8750 - 0.9681 |
| 52 Week Range | 0.5000 - 11.4700 |
| Volume | |
| Avg. Volume | 352,027 |
| Market Cap | 45.786M |
| Beta (5Y Monthly) | 1.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.0020 |
| Earnings Date | Nov 09, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.50 |
- GlobeNewswire
Applied Therapeutics Reports Third Quarter 2022 Financial Results
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022. “In the third quarter, we made significant progress across all three of our late-stage programs,” said Shoshana Shendelman, PhD, Founder, CEO and C
- GlobeNewswire
Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022
Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodelingBaseline analysis of Phase 3 ARISE-HF study supports the primary endpoint (cardiac functional capacity as measured by Peak VO2) as an important metric of quality of life and physical functioning in Diabetic Cardiomyopathy patients NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical
- GlobeNewswire
Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy
ARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placeboPrimary study endpoint is cardiac functional capacity (measured by Peak VO2) at 15 monthsDbCM is a form of heart failure affecting approximately 20% of Type 2 Diabetes patients (~6M patients in the US and ~5M in EU), which represents a significant commercial market opportunityThere are currently no treatme
